Herzinsuffizienz (HI) ist die häufigste Ursache für Hospitalisierungen bei Patienten über 65 Jahre.
Die Vasodilatatorentherapie bildet den Eckstein der Therapie der chronischen HI.
Trotz schwacher Evidenzlage kommen Vasodilatatoren auch bei der akuten HI zum Einsatz.
Levosimendan ist bei der akuten HI nur indiziert, wenn die β-Blockade als ursächlich erachtet wird.
Serelaxin ist ein vielversprechender neuer Ansatz. Hier fehlen jedoch noch abschließende klinische Studien.
Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.
1 Alla F, Zannad F, Filippatos G, Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007; 12(2):91–5
2 Sartorio CL et al., Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007; 50(5):919–25
3 McMurray JJ et al., Guidelines ESCCfP. ESC Guidelines f
or the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33(14):1787–847
4 Wakai A et al., Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013; 8:CD005151
5 García-González MJ et al., Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study. Cardiovasc Drugs Ther 2013; 27(6):573–9
6 Packer M et al., Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013; 1(2):103–11
7 Cuffe MS et al., Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure I. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287(12):1541–7
8 Berger R et al., Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail 2007; 9(2):202–8
9 Teerlink JR et al., Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381(9860):29–39
10 Cleland JG et al., Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circ Heart Fail 2014; 7(1):76–87
11 Testani JM et al., Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 2014; 7(2):261–70
